JP5346911B2 - 合成ヘパリン結合成長因子類似体 - Google Patents
合成ヘパリン結合成長因子類似体 Download PDFInfo
- Publication number
- JP5346911B2 JP5346911B2 JP2010262096A JP2010262096A JP5346911B2 JP 5346911 B2 JP5346911 B2 JP 5346911B2 JP 2010262096 A JP2010262096 A JP 2010262096A JP 2010262096 A JP2010262096 A JP 2010262096A JP 5346911 B2 JP5346911 B2 JP 5346911B2
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- fgf
- heparin
- growth factor
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C(***)=O)NC(C(C(*1)I1N**)N)=O Chemical compound CC(C(***)=O)NC(C(C(*1)I1N**)N)=O 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
- C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Description
本出願は、2002年8月20日に提出された「合成ヘパリン結合成長因子類似体」と題される米国特許出願番号第10/224,268号の一部継続出願であり、そしてそれに対して優先権を主張し、そしてその明細書は、ここに参照して組み込まれる。
本発明は、米国エネルギー省により授与される契約番号DE−AC02−98CH10886号の下に米国連邦政府支援を伴い発明された。米国連邦政府が本発明のあらゆる権利を有する。
各Xは、(i)最小3個のアミノ酸残基を有し、(ii)最大約50個のアミノ酸残基を有し、そして(iii)ヘパリン結合成長因子レセプター(HBGFR)を結合するペプチド鎖である;R1は、アミノ酸残基であり、Xは、R1のN末端を通して、またはR1の側鎖を通して共有結合で結合されている;R2は、三官能性アルファアミノ酸残基であり、Xは、R2の側鎖を通して共有結合で結合されている;Yは、n=0の場合、R1およびZに、またはn=1の場合、R2およびZに共有結合で結合された0個から約50個の原子までの鎖を包含するリンカーである;Zは、ヘパリン結合ドメインを包含する非シグナル発生ペプチド鎖であり、そして(i)最小1個のヘパリン結合モチーフ、(ii)最大約10個のヘパリン結合モチーフ、および(iii)最大約30個のアミノ酸を包含するアミノ酸配列を包含する;そしてnは、0または1であり、n=1の場合、ペプチド鎖Xは同一である。
R3およびR5は、独立に、NH2;N末端NH2、NH3 +、またはNH基あるいは対応のアシル化誘導体を含む、線状または分岐C1からC17までのアルキル、アリール、ヘテロアリール、アルケン、アルケニルまたはアラルキル鎖を有するアシル基であるか、またはN末端NH2、NH3 +、NH基あるいは対応のアシル化誘導体を有するアミノ酸、ジペプチドまたはトリペプチドである;R4は、−OH、NH2、NH−R6であるか、またはC末端−OH、NH2、またはNH−R6を有するアミノ酸、ジペプチドまたはトリペプチドである;R6は、脂肪族C1からC17までの鎖である;各Xは、(i)最小3個のアミノ酸残基を有し、(ii)最大約50個のアミノ酸残基を有し、そして(iii)HBGFRを結合するペプチド鎖である;J1およびJ2は、各々独立に、各Xが、J1およびJ2の側鎖を通して共有結合で結合される三官能性アルファアミノ酸残基である;Yは、n=0である場合、J1およびZに、あるいはn=1である場合、J2およびZに共有結合で結合された0から約50個までの原子の鎖を包含するリンカーである;Zは、ヘパリン結合ドメインを包含する非シグナル発生ペプチドであり、そして(i)最小1個のヘパリン結合モチーフ、(ii)最大約10個のヘパリン結合モチーフ、および(iii)最大約30個のアミノ酸を包含するアミノ酸配列を包含する;そしてnは、0または1であり、n=1の場合、合成ペプチド鎖Xは同一である。
式IからIVまでのヘパリン結合成長因子
式IからIVまでの合成HBGF類似体の領域XおよびZは、アミノ酸残基を含み、そして都合により領域Yは、アミノ酸残基を含む。アミノ酸残基は、Rが水素またはあらゆる有機基でありうる−NHRCO−として定義される。アミノ酸は、D−アミノ酸またはL−アミノ酸でありうる。さらに、アミノ酸は、アミノ酸の炭素鎖の長さによって、α−アミノ酸、β−アミノ酸、γ−アミノ酸、またはδ−アミノ酸などでありうる。
FGF合成類似体
別の特定の態様では、本発明は、合成FGFペプチド類似体を提供する。Xが、FGF類似体である、式IからIVまでのいずれかによって表される合成FGF類似体は、23のFGF−1からFGF−23まですべてを含めた既知FGFのいずれかのようなすべてのFGFでありうるFGFの類似体である。
別の特定の態様では、本発明は、合成VEGFペプチド類似体を提供する。示される合成VEGF類似体は、1つの実施態様では、X領域のアミノ酸配列がAPMAEGGGQNHHEVVKFMDV(配列番号:12)であるVEGF類似体を含む。別の実施態様では、X領域のアミノ酸配列がGATWLPPNPTK(配列番号:13)である合成VEGFペプチド類似体を提供する。さらに別の実施態様では、X領域のアミノ酸配列がNFLLSWVHWSLALLLYLHHA(配列番号:14)である合成VEGFペプチド類似体を提供する。
別の特定の態様では、本発明は、合成BMPペプチド類似体を提供する。合成骨形成タンパク質類似体は、X領域がアミノ酸配列LYVDFSDVGWNDW(配列番号:15)、AISMLYLDENEKVVL(配列番号:16)、ISMLYLDENEKVVLKNY(配列番号:17)、EKVVLKNYQDMVVEG(配列番号:18)、LVVKENEDLYLMSIAC(配列番号:19)、AFYCHGECPFPLADHL(配列番号:20)、またはPFPLADHLNSTNHAIVQTLVNSV(配列番号:21)である実施態様を含む。
本発明の類似体の合成は、当業界で周知である多様な化学的方法のいずれかにより達成されうる。このような方法は、ベンチスケールの固相合成および市販で入手可能な多くのペプチド合成機のいずれか1つでの自動ペプチド合成を含む。好ましくは、合成機は、99パーセントより大きな周期当たりのカップリング効率を示す。
本発明のHBGF類似体は、例えば、種々の疾患の予防または治療のための溶解性薬剤としての投与のように、溶解性予防薬または治療用医薬製剤としてを含めて、例えば癌療法および放射線防御での使用を含めて、多くの点で有用である生物学的に活性な分子の費用効率の高い、そして潜在的に制限のない源を提供する。
繊維芽細胞成長因子FGFは、間葉、上皮、および神経外胚葉の細胞型の正常な成長および分化を制御する関連タンパク質のファミリーを構築する。相同体は、広範で多様な種で見られた。FGFは、ヘパリンに非常に高い親和性を示し、したがって、ヘパリン結合成長因子(HBGF)とも称される。ここで使用される場合、用語「HBGF」は、全てのFGFを含む。
Claims (7)
-
式II
R3およびR5は、各々独立に、NH2;N末端NH2、NH3 +、NH基あるいは対応するアシル化誘導体を含む、直鎖または分岐C1からC17までのアルキル、アリール、ヘテロアリール、アルケン、アルケニルまたはアラルキル鎖を有するアシル基であるか、またはN末端NH2、NH3 +、NH基あるいは対応するアシル化誘導体を有するアミノ酸、ジペプチドまたはトリペプチドである;
R4は、−OH、NH2、NH−R6であるか、またはC末端−OH、NH2、またはNH−R6を有するアミノ酸、ジペプチドまたはトリペプチドである;
R6は、脂肪族C1からC17までの鎖である;
各Xは、配列番号6〜21から選択され;
J1およびJ2は、各々独立に、三官能性アルファアミノ酸残基であり、各Xは、J1およびJ2の側鎖を通して共有結合で結合される;
Yは、3個のアミノヘキサン酸残基の鎖からなるリンカーある;
Zは、配列番号2のヘパリン結合ドメインからなる非シグナルペプチド、
nは、0または1であり、n=1の場合、合成ペプチド鎖Xは同一である、
式IIで表されるヘパリン結合成長因子(HBGF)類似体を、その表面に、非共有結合を介して、被覆した医療用デバイスを供し、そして哺乳類の表面上に医療用デバイスを乗せるか、またはその中に医療用デバイスを移植することを包含する、活性ヘパリン結合成長因子類似体を哺乳類に送出するデバイス。 - 医療用デバイスは、縫合糸、移植片材料、外傷被覆材、神経ガイド、骨ワックス、動脈瘤コイル、塞栓形成粒子、微細ビーズ、ステント、歯科移植片、または骨プロテーゼ、組織足場、または徐放性薬剤送出デバイスである請求項1に記載のデバイス。
- 非共有結合は、合成ヘパリン結合成長因子類似体のヘパリン結合ドメインと、医療用デバイスの表面に結合したヘパリン含有化合物の間の結合である請求項1に記載のデバイス。
- ヘパリン含有化合物は、ベンジル−ビス(ジメチルシリルメチル)オキシカルバモイル−ヘパリンである請求項3に記載のデバイス。
- 医療用デバイスの表面は、ステンレス鋼、チタン、プラチナ、タングステン、セラミックス、ポリウレタン、ポリテトラフルオロエチレン、伸縮ポリテトラフルオロエチレン、ポリカーボネート、ポリエステル、ポリプロピレン、ポリエチレン、ポリスチレン、ポリ塩化ビニル、ポリアミド、ポリアクリレート、ポリウレタン、ポリビニルアルコール、ポリカプロラクトン、ポリラクチド、ポリグリコライド、ポリシロキサン、天然ゴム、人工ゴム、ブロック重合体またはブロック重合体の共重合体である請求項1に記載のデバイス。
- ポリシロキサンが、2,4,6,8−テトラメチルシクロテトラシロキサンである請求項5に記載のデバイス。
- X及びZは合成ペプチド鎖である請求項1に記載のデバイス。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/224,268 US7166574B2 (en) | 2002-08-20 | 2002-08-20 | Synthetic heparin-binding growth factor analogs |
US10/224,268 | 2002-08-20 | ||
US10/644,703 US7700563B2 (en) | 2002-08-20 | 2003-08-19 | Synthetic heparin-binding factor analogs |
US10/644,703 | 2003-08-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004529777A Division JP4712383B2 (ja) | 2002-08-20 | 2003-08-20 | 合成ヘパリン結合成長因子類似体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011078806A JP2011078806A (ja) | 2011-04-21 |
JP5346911B2 true JP5346911B2 (ja) | 2013-11-20 |
Family
ID=31886782
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004529777A Expired - Fee Related JP4712383B2 (ja) | 2002-08-20 | 2003-08-20 | 合成ヘパリン結合成長因子類似体 |
JP2010262096A Expired - Fee Related JP5346911B2 (ja) | 2002-08-20 | 2010-11-25 | 合成ヘパリン結合成長因子類似体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004529777A Expired - Fee Related JP4712383B2 (ja) | 2002-08-20 | 2003-08-20 | 合成ヘパリン結合成長因子類似体 |
Country Status (2)
Country | Link |
---|---|
US (2) | US7166574B2 (ja) |
JP (2) | JP4712383B2 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050271701A1 (en) * | 2000-03-15 | 2005-12-08 | Orbus Medical Technologies, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US8088060B2 (en) * | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US20160287708A9 (en) * | 2000-03-15 | 2016-10-06 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
US9522217B2 (en) * | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US7598224B2 (en) | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
US8227411B2 (en) | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
US7166574B2 (en) * | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
US7414028B1 (en) * | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
US20060024347A1 (en) * | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
WO2005082005A2 (en) | 2004-02-20 | 2005-09-09 | Biosurface Engineering Technologies, Inc., Et Al. | Positive modulator of bone morphogenic protein-2 |
EP1771214A2 (en) * | 2004-06-16 | 2007-04-11 | Affinergy Inc. | Biofunctional coatings |
US20090111743A1 (en) * | 2005-02-25 | 2009-04-30 | Biosurface Engineering Technologies, Inc. | Cysteine-branched heparin-binding growth factor analogs |
US7807624B2 (en) * | 2006-01-11 | 2010-10-05 | Affinergy, Inc. | Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices |
US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
JP2009541358A (ja) | 2006-06-22 | 2009-11-26 | バイオサーフェス エンジニアリング テクノロジーズ,インク. | 骨形成を強化するためにbmp−2増幅因子/共活性化因子を送達するための組成物および方法 |
US9187517B2 (en) * | 2006-11-13 | 2015-11-17 | The Brigham And Women's Hospital, Inc. | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
JP2010517638A (ja) * | 2007-02-02 | 2010-05-27 | トアニエ, インコーポレイテッド | 腱および靱帯を修復するシステムおよび方法 |
WO2008103265A2 (en) * | 2007-02-16 | 2008-08-28 | The Brigham And Women's Hospital, Inc. | Methods of using ledgf/p75 |
US20080255041A1 (en) * | 2007-04-11 | 2008-10-16 | Ebi, L.P. | Treatment of annulus fibrosis defects |
KR101171958B1 (ko) * | 2009-09-17 | 2012-08-08 | 한국과학기술연구원 | 헤파린 결합 도메인을 이용한 지방줄기세포의 지방세포로의 분화방법 |
CN102695501A (zh) | 2009-11-09 | 2012-09-26 | 聚光灯技术合伙有限责任公司 | 碎裂水凝胶 |
JP5864429B2 (ja) | 2009-11-09 | 2016-02-17 | スポットライト テクノロジー パートナーズ エルエルシーSpotlight Technology Partners Llc | 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット |
WO2012075243A2 (en) | 2010-12-01 | 2012-06-07 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeting sites of neovascular growth |
US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
JP5918909B2 (ja) | 2012-06-25 | 2016-05-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 標的化治療薬 |
EP2864353B1 (en) | 2012-06-25 | 2019-03-27 | The Brigham and Women's Hospital, Inc. | Selective cartilage therapy |
EP3316922A4 (en) | 2015-06-30 | 2019-04-03 | University of South Florida | OSTEO CONDUCTIVE AND OSTEOINDUCTIVE IMPLANT FOR REINFORCEMENT, STABILIZATION OR DEFECT RECONSTRUCTION |
CN110437306A (zh) * | 2019-07-24 | 2019-11-12 | 西北工业大学 | 基于希夫碱保护的无溶剂机械化学n→c多肽合成方法及回收方法 |
EP4181945A1 (en) * | 2020-07-15 | 2023-05-24 | University of Florida Research Foundation, Incorporated | Fibroblast growth factor 7 peptide |
CN113223607B (zh) * | 2021-05-28 | 2023-10-20 | 北京化工大学 | 采用smiles算法随机批量生成肝素类似物结构坐标的方法 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3272204A (en) | 1965-09-22 | 1966-09-13 | Ethicon Inc | Absorbable collagen prosthetic implant with non-absorbable reinforcing strands |
US4172128A (en) | 1975-03-26 | 1979-10-23 | Erhard Thiele | Process of degrading and regenerating bone and tooth material and products |
US4193138A (en) | 1976-08-20 | 1980-03-18 | Sumitomo Electric Industries, Ltd. | Composite structure vascular prostheses |
US4842575A (en) | 1984-01-30 | 1989-06-27 | Meadox Medicals, Inc. | Method for forming impregnated synthetic vascular grafts |
US5197977A (en) | 1984-01-30 | 1993-03-30 | Meadox Medicals, Inc. | Drug delivery collagen-impregnated synthetic vascular graft |
US4563350A (en) | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
GB8430265D0 (en) | 1984-11-30 | 1985-01-09 | Vascutek Ltd | Vascular graft |
US5859208A (en) | 1988-07-06 | 1999-01-12 | Fiddes; John C. | Human basic fibroblast growth factor analog |
US5658894A (en) | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US6919308B2 (en) | 1988-04-08 | 2005-07-19 | Stryker Corporation | Osteogenic devices |
US5108436A (en) | 1988-09-29 | 1992-04-28 | Collagen Corporation | Implant fixation |
US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5576288A (en) | 1989-04-27 | 1996-11-19 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
US5759515A (en) | 1989-08-09 | 1998-06-02 | Rhomed Incorporated | Polyvalent peptide pharmaceutical applications |
US5380536A (en) | 1990-10-15 | 1995-01-10 | The Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
US5270197A (en) | 1990-12-20 | 1993-12-14 | The Children's Medical Center Corporation | Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor |
US5728802A (en) | 1992-05-06 | 1998-03-17 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1) |
US5643873A (en) | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
US5648458A (en) | 1992-05-06 | 1997-07-15 | Affymax Technologies N.V. | Peptides and compounds that bind to ELAM-1 |
ATE314479T1 (de) | 1992-05-18 | 2006-01-15 | Genentech Inc | Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden |
US5684136A (en) | 1992-05-18 | 1997-11-04 | Genentech, Inc. | Chimeric hepatocyte growth factor (HGF) ligand variants |
US5643756A (en) | 1992-08-28 | 1997-07-01 | The Public Health Research Institute Of The City Of New York, Inc. | Fusion glycoproteins |
US5679673A (en) | 1992-09-24 | 1997-10-21 | The United States Of America, Represented By The Department Of Health And Human Services | Aralkyl bridged diazabicycloalkane derivatives for CNS disorders |
US6057133A (en) | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
US5674977A (en) | 1993-02-05 | 1997-10-07 | The Ontario Cancer Institute | Branched synthetic peptide conjugate |
US6001364A (en) | 1993-05-05 | 1999-12-14 | Gryphon Sciences | Hetero-polyoxime compounds and their preparation by parallel assembly |
US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
US5563046A (en) | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
US6284503B1 (en) | 1993-08-20 | 2001-09-04 | University Of Utah Research Foundation | Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces |
US5952304A (en) | 1993-10-22 | 1999-09-14 | Trigen Limited | Platelet-derived growth factor analogues |
US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5786331A (en) | 1994-02-02 | 1998-07-28 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5861476A (en) | 1994-02-02 | 1999-01-19 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5880096A (en) | 1994-02-02 | 1999-03-09 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US5589359A (en) | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
US5665114A (en) | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5509899A (en) | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5668110A (en) | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6251864B1 (en) | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5654276A (en) | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
DE69636289T2 (de) | 1995-12-18 | 2007-05-10 | Angiodevice International Gmbh | Vernetzten polymerisatmassen und verfahren für ihre verwendung |
GB9608882D0 (en) | 1996-04-30 | 1996-07-03 | Luthra Ajay K | Non-thrombogenic and anti-thrombogenic polymers |
US5811151A (en) | 1996-05-31 | 1998-09-22 | Medtronic, Inc. | Method of modifying the surface of a medical device |
US5965532A (en) | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
US6306165B1 (en) | 1996-09-13 | 2001-10-23 | Meadox Medicals | ePTFE small caliber vascular grafts with significant patency enhancement via a surface coating which contains covalently bonded heparin |
EP2264175B1 (en) | 1996-10-16 | 2012-11-21 | ZymoGenetics, Inc. | Fibroblast growth factor homologs |
US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
US6214795B1 (en) | 1996-11-12 | 2001-04-10 | Praecis Pharmaceuticals, Inc. | Peptide compounds useful for modulating FGF receptor activity |
AU6267798A (en) | 1997-02-07 | 1998-08-26 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
EP1001968B1 (en) | 1997-06-13 | 2004-12-22 | Gryphon Therapeutics, Inc. | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution |
US6168784B1 (en) | 1997-09-03 | 2001-01-02 | Gryphon Sciences | N-terminal modifications of RANTES and methods of use |
US5955588A (en) | 1997-12-22 | 1999-09-21 | Innerdyne, Inc. | Non-thrombogenic coating composition and methods for using same |
US6121236A (en) | 1998-03-24 | 2000-09-19 | The Children's Medical Center Corporation | Multivalent ligands which modulate angiogenesis |
DE19814057B4 (de) | 1998-03-30 | 2009-01-02 | Carl Zeiss Meditec Ag | Anordnung zur optischen Kohärenztomographie und Kohärenztopographie |
US6258371B1 (en) | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
WO2000006243A2 (en) | 1998-07-28 | 2000-02-10 | Innerdyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
WO2000012536A2 (en) | 1998-08-31 | 2000-03-09 | Gryphon Sciences | Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides |
US6342591B1 (en) | 1998-09-22 | 2002-01-29 | Biosurface Engineering Technologies, Inc. | Amphipathic coating for modulating cellular adhesion composition and methods |
US6548634B1 (en) | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
US6309660B1 (en) | 1999-07-28 | 2001-10-30 | Edwards Lifesciences Corp. | Universal biocompatible coating platform for medical devices |
US6458162B1 (en) | 1999-08-13 | 2002-10-01 | Vita Special Purpose Corporation | Composite shaped bodies and methods for their production and use |
EP1274468A1 (en) | 1999-12-28 | 2003-01-15 | Osteotech, Inc., | Calcium phosphate bone graft material and osteoimplant fabricated therefrom |
EP1156524B1 (en) | 2000-05-15 | 2014-10-22 | Micron Technology, Inc. | Manufacturing process of an integrated circuit including high-density and logic components portion |
KR20030036591A (ko) | 2000-07-12 | 2003-05-09 | 그리폰 테라퓨틱스, 인코포레이티드 | 폴리머-변형 생물활성 합성 키모카인, 및 그것의 제조와사용방법 |
CZ2003678A3 (cs) | 2000-09-08 | 2004-03-17 | Gryphon Therapeutics, Inc. | Syntetické proteiny stimulující erytropoézu |
US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
US7297343B2 (en) | 2001-07-31 | 2007-11-20 | Biosurface Engineering Technologies, Inc. | Bioactive medical films |
US7598224B2 (en) | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
US7166574B2 (en) | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
US8227411B2 (en) | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
US7468210B1 (en) | 2002-12-10 | 2008-12-23 | Biosurface Engineering Technologies, Inc. | Cross-linked heparin coatings and methods |
US7414028B1 (en) | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
US20060024347A1 (en) | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
US20080227696A1 (en) | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
US7528105B1 (en) | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
WO2005082005A2 (en) | 2004-02-20 | 2005-09-09 | Biosurface Engineering Technologies, Inc., Et Al. | Positive modulator of bone morphogenic protein-2 |
US20090111743A1 (en) | 2005-02-25 | 2009-04-30 | Biosurface Engineering Technologies, Inc. | Cysteine-branched heparin-binding growth factor analogs |
JP2009541358A (ja) | 2006-06-22 | 2009-11-26 | バイオサーフェス エンジニアリング テクノロジーズ,インク. | 骨形成を強化するためにbmp−2増幅因子/共活性化因子を送達するための組成物および方法 |
-
2002
- 2002-08-20 US US10/224,268 patent/US7166574B2/en not_active Expired - Fee Related
-
2003
- 2003-08-19 US US10/644,703 patent/US7700563B2/en not_active Expired - Fee Related
- 2003-08-20 JP JP2004529777A patent/JP4712383B2/ja not_active Expired - Fee Related
-
2010
- 2010-11-25 JP JP2010262096A patent/JP5346911B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20040038348A1 (en) | 2004-02-26 |
US7700563B2 (en) | 2010-04-20 |
JP2006509730A (ja) | 2006-03-23 |
US7166574B2 (en) | 2007-01-23 |
JP2011078806A (ja) | 2011-04-21 |
US20040087505A1 (en) | 2004-05-06 |
JP4712383B2 (ja) | 2011-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5346911B2 (ja) | 合成ヘパリン結合成長因子類似体 | |
US7598224B2 (en) | Dual chain synthetic heparin-binding growth factor analogs | |
US8101570B2 (en) | Single branch heparin-binding growth factor analogs | |
US20060024347A1 (en) | Bioactive peptide coatings | |
US7528105B1 (en) | Heterodimeric chain synthetic heparin-binding growth factor analogs | |
US7414028B1 (en) | Growth factor analogs | |
US9670258B2 (en) | Positive modulator of bone morphogenic protein-2 | |
US8227411B2 (en) | FGF growth factor analogs | |
US20090111743A1 (en) | Cysteine-branched heparin-binding growth factor analogs | |
EP1539801B1 (en) | Synthetic heparin-binding growth factor analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130129 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130426 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130502 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130527 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130625 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130723 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130819 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |